Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Neoadjuvant Surrogate Endpoint Is Tough Sell, But FDA Panel Says Perjeta Worth A Chance

23 Sep 2013

• By Sue Sutter

Related Content

FDA Breast Cancer Guidance Paves Way For Accelerated Approval With One Trial

29 May 2012

Final <em>Perjeta</em> Overall Survival Data Delayed By Its Efficacy

08 Dec 2012

<em>Perjeta</em>, <em>Avastin</em> Breast Cancer Approvals Are A Study In Contrasts

25 Jun 2012

“Not Another <em>Avastin</em>,” FDA Panel Warns Genentech At <em>Perjeta</em> Review

16 Sep 2013

Related Companies

Genentech, Inc.

Additional Topics

United States Advisory Committees BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.